Karampetsou Kalliopi, Koutsoni Olga S, Dotsika Eleni
Laboratory of Cellular Immunology & National Reference Laboratory for Leishmaniasis, Department of Microbiology, Hellenic Pasteur Institute, 127 Vass. Sofias av., 11521 Athens, Greece.
Division of Pharmacognosy and Natural Products Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.
Bio Protoc. 2019 Dec 5;9(23):e3442. doi: 10.21769/BioProtoc.3442.
Leishmaniasis is a parasitic disease caused by the obligatory intracellular protozoa spp. Current therapeutic options are limited and thus, drug discovery against leishmaniasis is very important. Nevertheless, there is a great difficulty to develop therapeutic strategies against the disease because the parasite deploys various mechanisms to evade the immune system and multiply inside the host. Among the main factors of the immunity that are recruited to confront the infection are the macrophages (MΦs) that produce effector molecules such as Nitric Oxide (NO) and Reactive Oxygen Species (ROS). Therefore, efficient drug agents should combine the antileishmanial effect of these gaseous transmitters along with the enhancement of the host's adaptive immunity. In the quest of therapeutic alternatives, natural products have been extensively studied and are considered as candidate antileishmanial agents since they exhibit specific properties in modulating the host's immune response towards an effective anti-leishmanial cell-mediated immunity capable to eliminate parasitic dissemination. In the current protocol, -infected MΦs (J774A.1 cell line) that have been treated with various increasing concentrations of a natural compound, are tested for the production of the aforementioned molecules. In order to detect NO production, we employ the Griess colorimetric nitrite assay and quantification relies on the construction of an accurate standard curve using appropriate standards of known concentration. ROS detection and quantification is achieved by flow cytometry and relies on the use of carboxy-HDCFDA, an indicator that converts to a fluorescent form when interacts with ROS molecules.
利什曼病是一种由专性细胞内原生动物利什曼原虫属引起的寄生虫病。目前的治疗选择有限,因此,针对利什曼病的药物研发非常重要。然而,开发针对该疾病的治疗策略存在很大困难,因为寄生虫会采用多种机制来逃避免疫系统并在宿主体内繁殖。在被招募来对抗感染的主要免疫因素中,巨噬细胞(MΦs)会产生诸如一氧化氮(NO)和活性氧(ROS)等效应分子。因此,有效的药物制剂应将这些气体递质的抗利什曼原虫作用与增强宿主的适应性免疫结合起来。在寻找治疗替代方案的过程中,天然产物已被广泛研究,并被视为候选抗利什曼原虫药物,因为它们在调节宿主免疫反应以形成能够消除寄生虫传播的有效抗利什曼原虫细胞介导免疫方面具有特定特性。在当前方案中,用各种浓度递增的天然化合物处理过的感染了利什曼原虫的MΦs(J774A.1细胞系),会被检测上述分子的产生情况。为了检测NO的产生,我们采用格里斯比色法测定亚硝酸盐,定量则依赖于使用已知浓度的适当标准品构建准确的标准曲线。ROS的检测和定量通过流式细胞术实现,依赖于使用羧基-HDCFDA这种指示剂,它在与ROS分子相互作用时会转化为荧光形式。